Patent ID: 11896592
Assignee: HUTCHISON MEDIPHARMA LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating cancer responsive to inhibition of c-Met, wherein the cancer is selected from lung cancer, stomach cancer, colorectal cancer, esophageal cancer, hepatocellular cancer, breast cancer, kidney cancer and ovarian cancer, comprising administering to a subject in recognized need thereof an effective amount of at least one compound of formula 1:, , and/or at least one pharmaceutically acceptable salt thereof, wherein:
X is N, Y is absent and R1 is a fused bicyclic heteroaryl selected from:, optionally substituted with one or more groups selected from halo, —CF3, —CF2H, cycloalkyl, —C(O)R11, —C(O)OR11, —CN, —C(O)NR13R14, —NR13R14, —NR13C(O)R11, —NR13S(O)nR12, —NR13S(O)nNR13R14, —NR13C(O)OR12, —NR13C(O)NR13R14, —NO2, —S(O)nR12, —S(O)nNR13R14, heterocycle, heteroaryl, aryl, alkenyl, alkynyl, lower alkyl, lower alkyl substituted with hydroxy, lower alkyl substituted with lower alkoxy, lower alkyl substituted with —NR13R14, and lower alkyl substituted with heterocycle;
R2 and R3 are independently selected from hydrogen, and alkyl, or R2 and R3, together with the carbon to which they are attached, form a ring chosen from 3- to 7-membered cycloalkyl and 3- to 7-membered heterocycle;
R4 is selected from halo, alkyl, cycloalkyl, heterocycle, aryl and heteroaryl, each of which, except for halo, is optionally substituted with one or more groups selected from:
(i) lower alkyl optionally substituted with one or more groups selected from hydroxy, lower alkoxy, cyano, halo, —C(O)OR11, —C(O)NR13R14, —NR13R14, —OC(O)R11, —NR13C(O)R11, —NR13S(O)nR12, —NR13S(O)nR13R14, —N13C(O)OR12, and —NR13C(O)NR13R14;
(ii) lower alkoxy optionally substituted with one or more groups selected from halo, hydroxy, and lower alkoxy;
(iii) cycloalkoxy optionally substituted with one or more groups selected from halo, hydroxy, and lower alkoxy;
(iv) heterocycloalkoxy optionally substituted with one or more groups selected from halo, hydroxy, and lower alkoxy;
(v) heterocycle optionally substituted with one or more groups selected from lower alkyl, halo, hydroxy, and lower alkoxy;
(vi) heteroaryloxy optionally substituted with one or more groups selected from lower alkyl, halo, hydroxy, and lower alkoxy;
(viii) aryl optionally substituted with one or more groups selected from lower alkyl, halo, hydroxy, and lower alkoxy;
(ix) heteroaryl optionally substituted with one or more groups selected from lower alkyl, halo, hydroxy, and lower alkoxy;
(x) halo;
(xi) cyano;
(xii) —C(O)R11;
(xiii) —C(O)OR11;
(xiv) —NR13R14;
(xv) —NR13C(O)R11;
(xvi) —NR13S(O)nR12;
(xvii) —NR13S(O)nNR13R14;
(xviii) —NR13C(O)OR12;
(xix) —NR13C(O)NR13R14;
(xx) —C(O)NR13R14,
(xxi) —S(O)nR12; and
(xxii) —S(O)nNR13R14;

R5 is selected from hydrogen, halo, OH, NH2, CF3, —CF2H, alkyl, alkenyl, and alkynyl;
each n is independently 0, 1, or 2;
R11, R12, R13, and R14 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, lower alkyl, hydroxy, and lower alkoxy, or R13 and R14, with the nitrogen to which they are attached, combine to form a heterocycle ring, which is optionally substituted with one or more groups selected from halo, lower alkyl, hydroxy, and lower alkoxy and further optionally includes one or two additional heteroatoms in the heterocycle ring wherein the one or two additional heteroatoms are selected from —O—, —S—, and —N(R15)—; and
R15 is selected from hydrogen, lower alkyl, —C(O)R11, —C(O)OR11, —C(O)NR13R14, —S(O)nR12, and —S(O)nNR13R14;
provided that:
when R2 is hydrogen or methyl and R3 and R5 are hydrogen, then R1 is not 3-quinazolin-6-yl;
wherein said at least one compound of formula (I), and/or at least one pharmaceutically acceptable salt thereof, is administered in conjunction with a protein tyrosine kinase inhibitor.